NASDAQ:CARM Carisma Therapeutics (CARM) Stock Forecast, Price & News $5.67 +0.68 (+13.63%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$5.04▼$5.7550-Day Range$2.82▼$6.5652-Week Range$2.75▼$19.30Volume200,800 shsAverage Volume123,494 shsMarket Capitalization$57.69 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Carisma Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.7% Upside$9.00 Price TargetShort InterestHealthy2.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.52) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector480th out of 1,006 stocksPharmaceutical Preparations Industry230th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingCarisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Carisma Therapeutics has a forecasted upside of 58.7% from its current price of $5.67.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.08% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CARM. Previous Next 3.3 News and Social Media Coverage News SentimentCarisma Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Carisma Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat Follows5 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Carisma Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.45% of the stock of Carisma Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($2.52) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCarisma Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Carisma Therapeutics (NASDAQ:CARM) StockCarisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.Read More Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARM Stock News HeadlinesMay 31, 2023 | msn.comCarisma Therapeutics Shines on New Cancer TreatmentMay 30, 2023 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023May 31, 2023 | Behind the Markets (Ad)The 4th Military Revolution is Happening. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>May 26, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Carisma Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CARM)May 26, 2023 | americanbankingnews.comCarisma Therapeutics, Inc. Forecasted to Post Q2 2023 Earnings of ($0.66) Per Share (NASDAQ:CARM)May 24, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Carisma Therapeutics (CARM) with Buy RecommendationMay 24, 2023 | americanbankingnews.comHC Wainwright Begins Coverage on Carisma Therapeutics (NASDAQ:CARM)May 15, 2023 | markets.businessinsider.comCarisma Therapeutics (CARM) Receives a Buy from Robert W. BairdMay 31, 2023 | Behind the Markets (Ad)The 4th Military Revolution is Happening. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>May 14, 2023 | uk.investing.comCarisma Therapeutics Inc (CARM)May 14, 2023 | americanbankingnews.comCarisma Therapeutics (CARM) vs. Its Peers Financial ContrastMay 11, 2023 | finanznachrichten.deCarisma Therapeutics Inc.: Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsMay 11, 2023 | finance.yahoo.comCarisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsMay 8, 2023 | finance.yahoo.comCarisma Therapeutics to Present at the JMP Securities Life Sciences ConferenceApril 17, 2023 | americanbankingnews.comCarisma Therapeutics (NASDAQ:CARM) Earns Outperform Rating from Analysts at Robert W. BairdApril 16, 2023 | americanbankingnews.comReviewing Cellectar Biosciences (NASDAQ:CLRB) and Carisma Therapeutics (NASDAQ:CARM)April 14, 2023 | finance.yahoo.comCarisma Therapeutics to Present at The American Association for Cancer Research Annual MeetingApril 6, 2023 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023April 4, 2023 | finanznachrichten.deCarisma Therapeutics Inc.: Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business HighlightsApril 4, 2023 | finance.yahoo.comCarisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business HighlightsMarch 30, 2023 | thestreet.comCarisma Therapeutics Inc.March 20, 2023 | finance.yahoo.comCarisma Therapeutics CEO Steven Kelly talks reverse merger, growth plansMarch 15, 2023 | seekingalpha.comCARM Carisma Therapeutics, Inc.March 11, 2023 | benzinga.comCARISMA Therapeutics Stock (NASDAQ:CARM), Earnings Estimates, EPS, and RevenueMarch 11, 2023 | benzinga.comCARISMA Therapeutics Stock (NASDAQ:CARM), DividendsMarch 11, 2023 | benzinga.comCARISMA Therapeutics Stock (NASDAQ:CARM), Guidance and ForecastMarch 11, 2023 | benzinga.comCARISMA Therapeutics Stock (NASDAQ:CARM), Analyst Ratings, Price Targets, PredictionsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARM Company Calendar Last Earnings5/11/2023Today5/31/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARM CUSIPN/A CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+100.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax Margin-1,126.41% Return on Equity-9.52% Return on Assets-7.29% Debt Debt-to-Equity Ratio0.01 Current Ratio6.73 Quick Ratio6.73 Sales & Book Value Annual Sales$40 million Price / Sales1.27 Cash Flow$3.56 per share Price / Cash Flow1.40 Book Value$8.46 per share Price / Book0.59Miscellaneous Outstanding Shares10,180,000Free Float9,849,000Market Cap$50.80 million OptionableNot Optionable Beta0.81 Key ExecutivesSteven KellyPresident, Chief Executive Officer & DirectorRichard Steven MorrisCFO, Treasurer & Chief Compliance OfficerMichael KlichinskyChief Scientific OfficerDaniel J. CushingChief Technology & Development OfficerKey CompetitorsMustang BioNASDAQ:MBIONRx PharmaceuticalsNASDAQ:NRXPNabriva TherapeuticsNASDAQ:NBRVASLAN PharmaceuticalsNASDAQ:ASLNAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 118,703 shares on 5/16/2023Ownership: 1.167%Susquehanna International Group LLPBought 94,600 shares on 5/16/2023Ownership: 0.000%State Street CorpBought 33,343 shares on 5/16/2023Ownership: 0.328%Wittenberg Investment Management Inc.Bought 46,703 shares on 5/15/2023Ownership: 0.459%CIBC Asset Management IncBought 14,971 shares on 5/12/2023Ownership: 0.147%View All Institutional Transactions CARM Stock - Frequently Asked Questions Should I buy or sell Carisma Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARM shares. View CARM analyst ratings or view top-rated stocks. What is Carisma Therapeutics' stock price forecast for 2023? 3 brokerages have issued 1 year price objectives for Carisma Therapeutics' shares. Their CARM share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 80.4% from the stock's current price. View analysts price targets for CARM or view top-rated stocks among Wall Street analysts. How have CARM shares performed in 2023? Carisma Therapeutics' stock was trading at $3.25 on January 1st, 2023. Since then, CARM shares have increased by 53.5% and is now trading at $4.99. View the best growth stocks for 2023 here. When is Carisma Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CARM earnings forecast. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics, Inc. (NASDAQ:CARM) issued its earnings results on Thursday, May, 11th. The company reported ($1.93) earnings per share for the quarter. The company earned $3.24 million during the quarter. What is Carisma Therapeutics' stock symbol? Carisma Therapeutics trades on the NASDAQ under the ticker symbol "CARM." Who are Carisma Therapeutics' major shareholders? Carisma Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Group One Trading L.P. (0.00%), BML Capital Management LLC (4.04%), BlackRock Inc. (1.29%), Geode Capital Management LLC (1.17%), Susquehanna International Group LLP (0.00%) and Renaissance Technologies LLC (0.67%). How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Carisma Therapeutics' stock price today? One share of CARM stock can currently be purchased for approximately $4.99. How much money does Carisma Therapeutics make? Carisma Therapeutics (NASDAQ:CARM) has a market capitalization of $50.80 million and generates $40 million in revenue each year. The company earns $-19,880,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. How can I contact Carisma Therapeutics? Carisma Therapeutics' mailing address is 245 1st St Ste 1800, Cambridge, Massachusetts 02142-1292. The company can be reached via phone at 617-444-8550, via email at ir@sesenbio.com, or via fax at 617-858-0911. This page (NASDAQ:CARM) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.